Confirmatory Clinical Study in Active Ulcerative Colitis
NCT07296315
This study is recruiting at 6 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
The main goal of the study is to check if MH002 works and is safe to use. In a previous study in 45 patients with Ulcerative Colitis, MH002 was found to have favorable effects. In this study, 2 different doses will be tested, and long-term treatment effects will be investigated. MH002 is a live biotherapeutic product (LBP). This is a biological medicine containing live bacteria used to restore the normal function of a gut that is damaged by ulcerative colitis (UC). Ulcerative colitis is a bowel disease that causes inflammation and sores in the gut.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Colitis, Ulcerative
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 16 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- MRM Health NV
- Last updated on ClinicalTrials.gov
- September 30, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 3
- ARA Professionals · Miami, FL
- Orlando Gastroenterology, P.A. · Orlando, FL
- Tropical Clinical Trials · Palmetto Bay, FL
North Carolina · 2
- Cross Creek Medical Clinic · Fayetteville, NC
- Peters Medical Research · High Point, NC
Texas · 1
- Southern Star Research Institute · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.